Leerink Partnrs Brokers Decrease Earnings Estimates for BMRN

Key Points

• Leerink Partners has reduced their Q3 2025 earnings per share (EPS) estimate for BioMarin Pharmaceutical to ($0.34), significantly down from a prior estimate of $0.78.
• Additionally, the consensus estimate for the company's current full-year earnings is $3.15 per share, with projections also issued for subsequent quarters and years.
• Despite the downgrade, 13 investment analysts have rated BioMarin stock with a Buy rating, leading to a consensus rating of "Moderate Buy" and an average price target of $93.26.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) - Equities research analysts at Leerink Partnrs cut their Q3 2025 EPS estimates for shares of BioMarin Pharmaceutical in a research note issued to investors on Wednesday, October 8th. Leerink Partnrs analyst J. Schwartz now forecasts that the biotechnology company will earn ($0.34) per share for the quarter, down from their prior estimate of $0.78. The consensus estimate for BioMarin Pharmaceutical's current full-year earnings is $3.15 per share. Leerink Partnrs also issued estimates for BioMarin Pharmaceutical's Q4 2025 earnings at $0.80 EPS, FY2025 earnings at $2.67 EPS, Q3 2026 earnings at $0.89 EPS, Q4 2026 earnings at $0.91 EPS, FY2026 earnings at $3.54 EPS and FY2027 earnings at $5.14 EPS.

Several other research firms have also weighed in on BMRN. Wolfe Research set a $95.00 price objective on shares of BioMarin Pharmaceutical and gave the stock an "outperform" rating in a research note on Tuesday, July 15th. UBS Group raised their target price on shares of BioMarin Pharmaceutical from $113.00 to $114.00 and gave the stock a "buy" rating in a report on Tuesday, August 5th. Wall Street Zen cut shares of BioMarin Pharmaceutical from a "strong-buy" rating to a "buy" rating in a report on Saturday. Weiss Ratings restated a "sell (d+)" rating on shares of BioMarin Pharmaceutical in a research report on Wednesday, October 8th. Finally, Wedbush restated an "outperform" rating and issued a $94.00 price target on shares of BioMarin Pharmaceutical in a research report on Tuesday, August 5th. Thirteen investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $93.26.

BioMarin Pharmaceutical Price Performance

BMRN opened at $52.32 on Monday. The firm has a market cap of $10.05 billion, a price-to-earnings ratio of 15.53, a price-to-earnings-growth ratio of 0.70 and a beta of 0.33. BioMarin Pharmaceutical has a fifty-two week low of $51.78 and a fifty-two week high of $73.51. The company's 50-day moving average price is $56.37 and its 200 day moving average price is $57.99. The company has a quick ratio of 3.60, a current ratio of 5.56 and a debt-to-equity ratio of 0.10.

Institutional Trading of BioMarin Pharmaceutical

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Dodge & Cox grew its position in BioMarin Pharmaceutical by 1.0% in the 2nd quarter. Dodge & Cox now owns 15,108,310 shares of the biotechnology company's stock worth $830,504,000 after purchasing an additional 153,070 shares during the last quarter. Viking Global Investors LP lifted its holdings in BioMarin Pharmaceutical by 13.8% during the 2nd quarter. Viking Global Investors LP now owns 12,288,611 shares of the biotechnology company's stock valued at $675,505,000 after purchasing an additional 1,488,552 shares during the last quarter. AQR Capital Management LLC lifted its holdings in BioMarin Pharmaceutical by 90.7% during the 2nd quarter. AQR Capital Management LLC now owns 5,580,573 shares of the biotechnology company's stock valued at $306,429,000 after purchasing an additional 2,654,768 shares during the last quarter. Geode Capital Management LLC lifted its holdings in BioMarin Pharmaceutical by 1.3% during the 2nd quarter. Geode Capital Management LLC now owns 3,474,438 shares of the biotechnology company's stock valued at $190,417,000 after purchasing an additional 43,185 shares during the last quarter. Finally, Nuveen LLC bought a new position in BioMarin Pharmaceutical during the 1st quarter valued at about $184,475,000. 98.71% of the stock is currently owned by institutional investors and hedge funds.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.